Profound Medical (NASDAQ: PROF) notes 78 TULSA-PRO systems in place as of 2025

Rhea-AI Filing Summary

Profound Medical Corp. filed a current report to share an operational update on its TULSA-PRO® technology platform. The company announced in a press release that its installed base of TULSA-PRO® systems stood at 78 systems as of December 31, 2025. This figure reflects the number of systems placed at customer sites by the end of the year.

The press release containing this information is furnished as an exhibit and is not deemed filed for liability purposes under U.S. securities laws or incorporated by reference into other SEC filings.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

False000162880800016288082026-01-122026-01-12iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 12, 2026

_______________________________

PROFOUND MEDICAL CORP.

(Exact name of registrant as specified in its charter)

_______________________________

Ontario, Canada	001-39032	Not Applicable
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2400 Skymark Avenue, Unit 6

Mississauga, Ontario, Canada L4W 5K5

(Address of Principal Executive Offices) (Zip Code)

Registrant's Telephone Number, Including Area Code: 647-476-1350

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares	PROF	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On January 12, 2026, Profound Medical Corp. (the “Company”) issued a press release announcing that the Company’s TULSA-PRO® installed base stood at 78 systems as of December 31, 2025. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated January 12, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PROFOUND MEDICAL CORP.
Date: January 12, 2026	By:	/s/ Rashed Dewan
		Rashed Dewan
		Chief Financial Officer

FAQ

What did Profound Medical Corp. (PROF) disclose in this 8-K?

Profound Medical Corp. disclosed that its TULSA-PRO® installed base stood at 78 systems as of December 31, 2025, as announced in a press release furnished with the report.

What is the key operational metric reported by Profound Medical Corp. (PROF)?

The key operational metric reported is the installed base of TULSA-PRO® systems, which reached 78 systems as of December 31, 2025.

How was the TULSA-PRO® information provided by Profound Medical Corp. (PROF)?

The information was provided through a press release dated January 12, 2026, which is included as Exhibit 99.1 to the report under Regulation FD Disclosure.

Is the TULSA-PRO® press release considered filed with the SEC for liability purposes?

No. The company states that the information under Item 7.01, including Exhibit 99.1, is furnished, not filed, and is not subject to the liabilities of Section 18 of the Exchange Act.

Does this Profound Medical Corp. (PROF) report include financial statements?

No. The report lists exhibits under Item 9.01, including the TULSA-PRO® press release (Exhibit 99.1) and the cover page interactive data file (Exhibit 104), but does not provide financial statements.

Who signed the Profound Medical Corp. (PROF) current report?

The report was signed on behalf of Profound Medical Corp. by Rashed Dewan, who is identified as the company’s Chief Financial Officer.